Adduct of fluorescent dye and tumor avid tetrapyrrole
    1.
    发明授权
    Adduct of fluorescent dye and tumor avid tetrapyrrole 有权
    荧光染料和肿瘤病毒四吡咯的加合物

    公开(公告)号:US07947729B2

    公开(公告)日:2011-05-24

    申请号:US11632433

    申请日:2005-07-13

    IPC分类号: C07B47/00 C07D487/22

    摘要: A compound having preferential localization in tumor tissue relative to normal tissue, a preferential electromagnetic absorption at a wavelength between about 660 and 900 nm, and a fluorescence at a wavelength shifted from the preferential absorption by at least +30 nm and preferably at least +50 nm. The compound further preferably destroys tumor tissue in which it is absorbed when exposed to light at its preferential absorption wavelength. In a preferred embodiment of the invention, the compound is a conjugate of a tumor avid tetrapyrrole compound with a fluorescent dye, and more preferably the fluorescent dye is an indocyanine dye such as indocyanine green. The tumor avid tetrapyrrole compound is preferably a porphyrin derivative selected from the group consisting of chlorins, bacteriochlorins, purpurins and derivatives thereof.

    摘要翻译: 相对于正常组织在肿瘤组织中优先定位的化合物,在约660和900nm之间的波长处的优先电磁吸收以及波长从优选吸收偏移至少±30nm,优选至少+50nm的荧光 nm。 该化合物进一步优选地破坏在其优先吸收波长下暴露于光时被吸收的肿瘤组织。 在本发明的一个优选实施方案中,化合物是肿瘤病毒四吡咯化合物与荧光染料的缀合物,更优选荧光染料是吲哚菁染料,如吲哚菁绿。 肿瘤病毒四吡咯化合物优选为选自二卟啉,细菌二氢卟酚,紫草素及其衍生物的卟啉衍生物。

    ADDUCT OF FLUORESCENT DYE AND TUMOR AVID TETRAPYRROLE
    2.
    发明申请
    ADDUCT OF FLUORESCENT DYE AND TUMOR AVID TETRAPYRROLE 有权
    荧光染色和肿瘤血小板衍生物的添加

    公开(公告)号:US20090043090A1

    公开(公告)日:2009-02-12

    申请号:US11632433

    申请日:2005-07-13

    IPC分类号: C09B47/00 C09B47/04

    摘要: A compound having preferential localization in tumor tissue relative to normal tissue, a preferential electromagnetic absorption at a wavelength between about 660 and 900 nm, and a fluorescence at a wavelength shifted from the preferential absorption by at least +30 nm and preferably at least +50 nm. The compound further preferably destroys tumor tissue in which it is absorbed when exposed to light at its preferential absorption wavelength. In a preferred embodiment of the invention, the compound is a conjugate of a tumor avid tetrapyrrole compound with a fluorescent dye, and more preferably the fluorescent dye is an indocyanine dye such as indocyanine green. The tumor avid tetrapyrrole compound is preferably a porphyrin derivative selected from the group consisting of chlorins, bacteriochlorins, purpurins and derivatives thereof.

    摘要翻译: 相对于正常组织在肿瘤组织中优先定位的化合物,在约660和900nm之间的波长处的优先电磁吸收以及波长从优选吸收偏移至少±30nm,优选至少+50nm的荧光 nm。 该化合物进一步优选地破坏在其优先吸收波长下暴露于光时被吸收的肿瘤组织。 在本发明的一个优选实施方案中,化合物是肿瘤病毒四吡咯化合物与荧光染料的缀合物,更优选荧光染料是吲哚菁染料,如吲哚菁绿。 肿瘤病毒四吡咯化合物优选为选自二卟啉,细菌二氢卟酚,紫草素及其衍生物的卟啉衍生物。

    Metallation enhancements in tumor-imaging and PDT therapy
    3.
    发明授权
    Metallation enhancements in tumor-imaging and PDT therapy 有权
    肿瘤成像和PDT治疗中的金属化增强

    公开(公告)号:US08609837B2

    公开(公告)日:2013-12-17

    申请号:US13168421

    申请日:2011-06-24

    IPC分类号: C07D487/22 G01N33/559

    摘要: A compound in the form of a metallized tetrpyrollic photosensizer linked to a fluorescent dye where the photosensitizer (PS), is linked by a structure that does not have detrimental radiation emmitance or absorbing characteristics, to a fluorophore, usually a cyanine dye (CD). The photosensitizer in accordance the invention is a metallized analog of porphyrins, chlorins, purpurinimides, bacterio pupurinimides, phthalocyanines, expanded porphyrins, benzoporphyrin derivatives and purpurins. The fluorophore is usually a cyanine dye with variable substituents. And, A method for determining effectiveness of PDT by comparing proportion of STAT-3 monomer with crosslinked STAT-3 dimer after PDT where the relative proportion of STAT-3 monomer to crosslinked STAT-3 directly correlates to efficacy of the PDT.

    摘要翻译: 与荧光染料连接的金属化四层光敏剂形式的化合物,其中光敏剂(PS)通过不具有有害辐射发射或吸收特性的结构连接到荧光团,通常为花青染料(CD)。 根据本发明的光敏剂是卟啉,二氢卟酚,紫嘌呤酰胺,细菌栀子酰胺,酞菁,膨胀卟啉,苯并卟啉衍生物和紫杉醇的金属化类似物。 荧光团通常是具有可变取代基的花青染料。 另外,通过比较PDT后STAT-3单体与交联的STAT-3二聚体的比例,其中STAT-3单体与交联的STAT-3的相对比例与PDT的功效直接相关,从而确定PDT有效性的方法。

    METALLATION ENHANCEMENTS IN TUMOR-IMAGING AND PDT THERAPY
    4.
    发明申请
    METALLATION ENHANCEMENTS IN TUMOR-IMAGING AND PDT THERAPY 有权
    肿瘤成像和PDT治疗中的金属增强

    公开(公告)号:US20120097538A1

    公开(公告)日:2012-04-26

    申请号:US13168421

    申请日:2011-06-24

    摘要: A compound in the form of a metallized tetrpyrollic photosensizer linked to a fluorescent dye where the photosensitizer (PS), is linked by a structure that does not have detrimental radiation emmitance or absorbing characteristics, to a fluorophore, usually a cyanine dye (CD). The photosensitizer in accordance the invention is a metallized analog of porphyrins, chlorins, purpurinimides, bacterio pupurinimides, phthalocyanines, expanded porphyrins, benzoporphyrin derivatives and purpurins. The fluorophore is usually a cyanine dye with varaible substituents. And, A method for determining effectiveness of PDT by comparing proportion of STAT-3 monomer with crosslinked STAT-3 dimer after PDT where the relative proportion of STAT-3 monomer to crosslinked STAT-3 directly correlates to efficacy of the PDT.

    摘要翻译: 与荧光染料连接的金属化四层光敏剂形式的化合物,其中光敏剂(PS)通过不具有有害辐射发射或吸收特性的结构连接到荧光团,通常为花青染料(CD)。 根据本发明的光敏剂是卟啉,二氢卟酚,紫嘌呤酰胺,细菌栀子酰胺,酞菁,膨胀卟啉,苯并卟啉衍生物和紫杉醇的金属化类似物。 荧光团通常是具有可变取代基的花青染料。 另外,通过比较PDT后STAT-3单体与交联的STAT-3二聚体的比例,其中STAT-3单体与交联的STAT-3的相对比例与PDT的功效直接相关,从而确定PDT有效性的方法。